U.S., Nov. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07951190) titled 'An Open-label Study to Evaluate the Long-Term Safety and Tolerability of Iptacopan in Patients With Complement Mediated Diseases.' on Nov. 11.

Brief Summary: The purpose of this single-arm, multicenter, Phase IIIb roll-over extension study is to assess the long-term safety, tolerability, and efficacy of iptacopan in participants with complement mediated diseases.

Study Start Date: Nov. 16

Study Type: INTERVENTIONAL

Condition: Complement Mediated Diseases e.g. PNH, IgAN

Intervention: DRUG: Iptacopan

Participants >12 years of age will receive iptacopan 200 mg twice daily, and participants aged 2 to <12 years will receive weight...